Hutchinson teen in coma after he was struck by driver while crossing street
Community rallies behind Minnesota student who is fighting for his life
Community rallies behind Minnesota student who is fighting for his life
Community rallies behind Minnesota student who is fighting for his life
A community is rallying together behind a high school student who is fighting for his life after he was hit by a car.
Mayson Buschel, 16, was crossing Main Street in Hutchinson last week when a driver ran into him.
Now, the entire community is drumming up support for Mayson and his family.
Inside the Qdoba restaurant in Hutchinson, the crew is preparing to help one of their own who is in a hospital in Minneapolis, fighting for his life.
"We are doing a fundraiser here 25% of the proceeds go the Mayson and his family, and the owners are going to match that and then all of our tips are going to go to that cause as well, " said Alex Stubeda, Qdoba's Assistant Manager.
"Awesome kid he's full of life funny I shouldn't even laugh at some of the things that comes out of his mouth," said Samantha Buschel.
Mayson's Buschel mother Samantha has been by his side at Hennepin Health Care in Minneapolis since the crash.
"Mayson is my rock he is who I have always had by my side since I was 20 years old," said Samantha Buschel.
Samantha Buschel says Mayson Buschel loves his siblings and is fiercely protective of them. She says he is a fighter, determined to get back to them and the friends he's known since they were in diapers.
Friend Jacson Vannurden says Mayson Buschel's life-of-the-party attitude has him hoping for the best.
"He can pull jokes out of nothing they can be the most random things, and he can make it funny," said Vannurden.
All are thankful the online fundraiser to help Mayson Buschel and his family is growing.
"I am truly mind blown at the support and a lot of it is coming from people who know Mayson. Contacts are the parents of the children are my son, my daughter they are so worried about Mayson I don't know where all the donations care coming from, I don't even know who these people are," said Samantha Buschel.
What she does know is she is grateful for the support.
Hennepin Health Care says Mayson Buschel is in critical condition.
Court records show the 23-year-old driver who hit him has 11 prior speeding convictions. She has not been charged in this case.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
36 minutes ago
- CBS News
Modesto school district's proposed "Puberty Talk" curriculum raises concerns
A controversy is brewing in Modesto as the local school district is considering adopting a new health curriculum called "Puberty Talk" for 5th graders. There's growing pushback not just from parents but from one of the district's board members over what the children should or shouldn't be learning about sex and gender. But Modesto City Schools says this is not sex education. It is health education. School board member Jolene Daly says the plan dives too deep into matters that are too adult for children. She's a licensed family therapist who says the lessons could cause students psychological harm. "They're not really understanding the psychological impact of some of the statements that are being made on the cognitive develop of the of these young kids," she said. CBS13 reviewed the material at the district's office. It includes chapters titled "Consent Plus Boundaries," "Identity Plus Expression" and "Puberty Health and Hygiene," which include discussions about different kinds of intercourse. "The hygiene portion of it tells them to make sure that they wash their hands and their genitals," Daly told CBS Sacramento over Zoom. "These 10 and 11-year-olds don't have the capacity to understand some of the information that is in the text." The district says the curriculum meets state requirements under the California Healthy Youth Act and that parents can opt out. But one mother of a student argues these are discussions that need to be had. "I think it's important to talk about it before those changes happen," the mother said. "I think normalizing things makes it better." The board took public comment on the material Monday night, and parents were able to see the material for themselves at the district's professional development building They'll vote on this matter on June 28.
CBS News
4 hours ago
- CBS News
Denver Fork Cancer event to fight cancer, raise awareness for patients one bite at a time
Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver Fundraiser called Fork Cancer to take place in July in Denver In Colorado, about one-in-two men and two-in-five women will be diagnosed with some form of cancer in their lifetimes. It's a common disease in our state, with about 25,000 Coloradans diagnosed every year. American Cancer Society Cancer Action Network But Fork Cancer, hosted by the American Cancer Society Cancer Action Network, is helping fight cancer. American Cancer Society Cancer Action Network The party with a purpose features Denver fine culinary establishments while offering a variety of small plates, spirits and brews, and live entertainment acts. Ocular melanoma survivor Katie Doble will also share her powerful story of resilience. American Cancer Society Cancer Action Network You're invited to Fork Cancer, July 17th at 6:30pm at Mile High Station. CBS Colorado Anchor Mekialaya White will host the event. Tickets are available here.
Medscape
4 hours ago
- Medscape
Part D Cancer Drug Launch Prices Soar Past Inflation
Launch prices for Medicare Part D anticancer drugs have risen sharply since 2012, with a mean increase of $1694 per year. In 2025, the observed prices were 15%-200% higher than expected if the increases were due to inflation alone, but the gap between observed and inflation-adjusted prices narrowed over the study period. METHODOLOGY: The Inflation Reduction Act of 2022 introduced price negotiation for Medicare-covered drugs and required manufacturers to pay rebates to Medicare for price increases above inflation. But it did not address the launch prices of new drugs. Anticancer drugs, a protected drug class with mandatory Medicare Part D coverage, may now be especially prone to higher launch prices, in part because the Inflation Reduction Act limits out-of-pocket spending and price increases after market entry. Researchers identified 86 branded, self-administered, molecularly targeted anticancer therapies approved by the FDA between January 2010 and December 2024. Data on drug prices were obtained from the Medicare Prescription Drug Plan Formulary and adjusted for inflation. The researchers looked at launch prices by year and compared drug prices in 2025 with those expected if launch prices had increased due to inflation alone since the drug's market entry. TAKEAWAY: The mean monthly launch price increased from $10,954 for drugs first observed in the Medicare formulary in 2012-2014 to $27,891 for drugs first observed in 2023-2025. After adjusting for inflation, the mean launch price increased by $1694 per year ( P < .001). < .001). In 2025, actual drug prices were 14.8%-200.9% higher than expected if they had only kept pace with inflation. Although the gap between observed and inflation-adjusted prices narrowed over time, price increases continued to outpace inflation in 2023 and 2024, despite the Inflation Reduction Act rebate requirement, which will result in rebates to Medicare starting in fall 2025. IN PRACTICE: 'Launch prices for self-administered targeted anticancer therapies have grown precipitously, although no evidence was found of disproportionate increases in recent years. Instead, continued launch price growth for anticancer therapies was observed, consistent with prior research,' the study authors wrote. 'This suggests that companies were already engaging in price maximization for anticancer therapies and continued to do so after the implementation of the [Inflation Reduction Act].' SOURCE: This study, led by Stacie B. Dusetzina, PhD, Vanderbilt University School of Medicine in Nashville, Tennessee, was published online in JAMA . LIMITATIONS: This study used example indications to determine monthly doses and pricing. Additionally, variations in available price measures were noted over the study period. DISCLOSURES: This study was funded by Arnold Ventures. Several authors reported receiving grants or personal fees and having other ties with various sources.
